IL2 and lupus nephritis: Primary end point: SRI-4 response at week 24 (IL-2: 65.5%, placebo: 36.7%; p=0.03), higher lupus nephritis remission rate, increase complement, reduction in anti-DNA antibodies in the IL-2 group. No SAE, increase in Treg cells in the IL-2 group.